Prostatic Neoplasms, Castration-Resistant
-
Subject Areas on Research
-
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
-
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
-
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
-
A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.
-
ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
-
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
-
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
-
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
-
An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
-
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
-
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
-
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
-
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
-
Biomarkers in castration-resistant prostate cancer.
-
Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.
-
Burden of disease matters when it comes to systemic therapy for prostate cancer.
-
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
-
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
-
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
-
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
-
Castration-resistant prostate cancer: from new pathophysiology to new treatment.
-
Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
-
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
-
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
-
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
-
Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
-
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
-
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
-
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
-
Clinical phenotypes of castration-resistant prostate cancer.
-
Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
-
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
-
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
-
DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
-
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
-
Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
-
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
-
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
-
Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
-
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
-
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
-
Emerging therapeutic targets for patients with advanced prostate cancer.
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
-
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
-
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
-
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
-
Hormone naïve prostate cancer: predicting and maximizing response intervals.
-
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
-
Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
-
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
-
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
-
Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
-
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
-
Integrative clinical genomics of advanced prostate cancer.
-
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
-
Making progress on progression in metastatic prostate cancer.
-
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
-
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
-
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.
-
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
-
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
-
New treatment options in castration-resistant prostate cancer.
-
New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?
-
Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train?
-
Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
-
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
-
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
-
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
-
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
-
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
-
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
-
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
-
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
-
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
-
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
-
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
-
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
-
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
-
Platinum sensitivity in metastatic prostate cancer: does histology matter?
-
Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
-
Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
-
Precision Medicine Approaches When Prostate Cancer Akts Up.
-
Preclinical and Coclinical Studies in Prostate Cancer.
-
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
-
Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
-
Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
-
Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
-
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
-
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
-
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
-
Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
-
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
-
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
-
Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
-
Racial Discrepancies in Overall Survival among Men Treated with 223Radium.
-
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
-
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
-
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
-
Reply to M.A.N. Şendur et al and J. Michels.
-
Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
-
SRRM4 gene expression correlates with neuroendocrine prostate cancer.
-
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
-
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.
-
Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
-
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
-
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
-
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
-
The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
-
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
-
The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
-
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
-
Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
-
Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
-
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
-
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.